Previous Article | Next Article ![]()
Department of Oncology, and Pharmacology, Lombardi Cancer Center, Georgetown University, Washington, D.C. 20057; ProtTech, Inc. Norristown, Pennsylvania 19403, U.S.A.; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, U.S.A.
* To whom correspondence should be addressed. Email:
ariege01{at}georgetown.edu.
Overexpression and activation of the steroid receptor coactivator AIB1/SRC-3 has been shown to have a critical role in oncogenesis; required for both steroid and growth factor signaling in epithelial tumors. Here, we report a new mechanism for activation of SRC coactivators. We demonstrate regulated tyrosine phosphorylation of AIB1/SRC-3 at a C-terminal tyrosine residue (Y1357) that is phosphorylated after IGF-1, EGF or estrogen treatment of breast cancer cells. Phosphorylated Y1357 is increased in HER2/neu mammary tumor epithelia and is required to modulate AIB1/SRC-3 coactivation of ER
Copyright (c) 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
Tyrosine phosphorylation of the nuclear receptor coactivator AIB1/SRC-3 is enhanced by Abl kinase and is required for its activity in cancer cells
![]()
, PR-B, NF-kB and AP-1 dependent promoters. c-Abl tyrosine kinase directly phosphorylates AIB1/SRC-3 at Y1357 and modulates the association of AIB1 with c-Abl, ER
, the transcriptional cofactor p300, and the methyltransferase CARM1. AIB1/SRC-3 dependent transcription and phenotypic changes, such as cell growth and focus formation, can be reversed by an Abl kinase inhibitor, imatinib. Thus, the phosphorylation state of Y1357 can function as a molecular on/off switch and facilitates the cross-talk between hormone, growth factor and intracellular kinase signaling pathways in cancer.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»